Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsRADX -1.42%33 Days Payable is 433.65 as of Jun. 2025, which is 43% below its 10-year median of 754.85. GuruFocus rates RADX with a GF Score™ of 33/100 and a GF Value™ of $2.34 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 708 Biotechnology companies, Radiopharm Theranostics ranks better than 82.06% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Radiopharm Theranostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Days Payable distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Radiopharm Theranostics's Days Payable for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (RADX) has a Days Payable of 433.65 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Radiopharm Theranostics and its competitors. This is 43% below median its historical median of 754.85. Over the past decade, Radiopharm Theranostics' Days Payable has ranged from 599.85 to 860.63. According to the industry distribution chart, Radiopharm Theranostics ranks #127 out of 708 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Radiopharm Theranostics' Days Payable too high?
Radiopharm Theranostics' current Days Payable of 433.65 is 43% below median its 10-year median of 754.85. Over the past 10 years, this metric has ranged from a low of 599.85 to a high of 860.63. The Biotechnology industry median Days Payable is 111.42. Radiopharm Theranostics' value of 433.65 is 289.2% above this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #127 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #127 out of 708 companies for Days Payable. This places Radiopharm Theranostics in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.42. Radiopharm Theranostics' value of 433.65 is 289.2% above this benchmark. Historically, Radiopharm Theranostics' own Days Payable has ranged from 599.85 to 860.63 over the past decade. While the company's 10-year median is 754.85 vs. the industry median of 111.42, Radiopharm Theranostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.42, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Days Payable of 433.65 is 289.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Days Payable is 111.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Days Payable is 433.65, which is 43% below median its own 10-year median of 754.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current Days Payable is 433.65, which is 43% below median its 10-year median of 754.85 and 289.2% above the Biotechnology industry median of 111.42. Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current Days Payable is 433.65 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Radiopharm Theranostics (RADX) Overvalued in 2026?
Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued.
The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34.
GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.
Key valuation signals for RADX:
Days Payable: 433.65 (43% below median its 10-year median of 754.85)
GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
Industry Position: 289.2% above the Biotechnology median (#127 of 708)
No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score
Get the complete analysis for RADX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RADX has been successfully added to your 
